Friday, May 31, 2019, Chicago, Illinois, 7:00 PM – 9:00 PM

Beyond the Guidelines: Clinical Investigator Perspectives on the Management of Lung Cancer

Location:
Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Time:
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:00 PM — Educational Meeting

Meeting Room:
Grand Ballroom (Level 2)

There is no registration fee for this event. However, preregistration is advised as seating is limited.  
 
Faculty:
D Ross Camidge, MD, PhD
Professor of Medicine/Oncology
Joyce Zeff Chair in Lung Cancer Research
University of Colorado, Anschutz Medical Campus
Denver, Colorado

Stephen V Liu, MD, PhD
Associate Professor of Medicine
Georgetown University Hospital
Washington, DC

Professor Solange Peters, MD, PhD
Head, Medical Oncology
Chair, Thoracic Malignancies
Oncology Department
Lausanne University Hospital (CHUV)
Lausanne, Switzerland


Gregory J Riely, MD, PhD
Associate Attending
Memorial Sloan Kettering Cancer Center
New York, New York

David R Spigel, MD
Chief Scientific Officer
Program Director, Lung Cancer Research
Sarah Cannon Research Institute
Nashville, Tennessee

Moderator:
Neil Love, MD
Research To Practice
Miami, Florida

Not an official event of the 2019 ASCO Annual Meeting. Not sponsored, endorsed, or accredited by ASCO, CancerLinQ, or Conquer Cancer.

This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, and Merck.
6:30 PM – 7:00 PM — Registration and Dinner Buffet
7:00 PM – 9:00 PM — Educational Meeting

Meeting Agenda and Format

To begin each module, results of interactive audience polling using networked iPads will be juxtaposed with the findings from a survey comprising case-based and related management questions completed by 25 clinical investigators prior to the meeting. Each faculty member will then deliver a presentation reviewing recently published research data and ongoing clinical trials related to the topics and questions addressed via the surveys. After each presentation, moderated panel discussion will take place to generate other relevant perspectives and dialogue.

MODULE 1: Optimal Therapeutic Approaches for Patients with Metastatic Non-Small Cell Lung Cancer (NSCLC) and EGFR Tumor Mutations — Dr Riely

  • Guideline-endorsed testing algorithms for patients with metastatic adenocarcinoma of the lung; validation of and indications, if any, for plasma assays to identify EGFR and other mutations/alterations
  • Available efficacy and safety data with osimertinib as first-line therapy for patients with EGFR tumor mutations
  • Documented activity of osimertinib in patients with CNS metastases
  • Recent FDA approval of dacomitinib as first-line therapy for patients with NSCLC and an EGFR tumor mutation and implications, if any, for patient care
  • Optimal treatment of disease that has progressed on first-line EGFR tyrosine kinase inhibitor therapy; clinical relevance of resistance mechanisms in patients experiencing progression on osimertinib

MODULE 2: Management of NSCLC with ALK Rearrangements or Other Targetable Abnormalities — Dr Camidge

  • Available clinical trial data informing the selection of first- and later-line therapy for patients with metastatic NSCLC and an ALK rearrangement
  • Design, eligibility criteria and key efficacy and safety outcomes from the Phase III ALTA-1L trial evaluating brigatinib versus crizotinib for patients with NSCLC and an ALK rearrangement who have not received prior treatment with an ALK inhibitor
  • Published efficacy and safety data with “next-generation” ROS1 inhibitors (eg, lorlatinib, entrectinib)
  • Mechanism of action of, available data with and ongoing evaluation of LOXO-292 in patients with RET fusion-driven NSCLC and other cancers
  • Early clinical trial results with and ongoing evaluation of novel agents targeting MET exon 14 mutations (eg, capmatinib, tepotinib)

MODULE 3: Current and Emerging Paradigms in the Treatment of Small Cell Lung Cancer (SCLC) — Dr Liu

  • Design of, eligibility criteria for and key efficacy and safety findings from the Phase III IMpower133 trial evaluating carboplatin/etoposide with or without atezolizumab for untreated extensive-stage SCLC
  • Recent FDA approval of carboplatin/etoposide/atezolizumab for extensive-stage SCLC; appropriate integration into current SCLC management
  • Research database supporting the FDA approval of nivolumab for patients with progressive SCLC; clinical implications of negative results from the Phase III CheckMate 331 trial comparing nivolumab to chemotherapy for patients with relapsed SCLC after first-line platinum-based chemotherapy
  • Published research experience with pembrolizumab in SCLC
  • Available efficacy and safety data with the use of anti-PD-1/PD-L1 antibodies in combination with anti-CTLA-4 antibodies for patients with progressive metastatic SCLC

MODULE 4: Integration of Immune Checkpoint Inhibition into the Management of Locally Advanced NSCLC — Dr Spigel

  • Preclinical and clinical research efforts documenting the synergistic effect of chemoradiation therapy and immune checkpoint inhibition
  • Design of, eligibility criteria for and key efficacy and safety findings from the Phase III PACIFIC trial evaluating the use of consolidation durvalumab after chemoradiation therapy for patients with unresectable Stage III NSCLC
  • Biologic rationale for the benefit observed with durvalumab in prespecified subgroups (eg, histology, presence of an actionable mutation, smoking status) in the PACIFIC trial
  • Rates of Grade 3/4 adverse events (AEs), including pneumonitis and other immune-mediated AEs, and treatment discontinuation among patients receiving durvalumab in the PACIFIC study
  • Rationale for and ongoing investigation of anti-PD-1/PD-L1 antibodies in nonmetastatic settings beyond consolidation therapy for locally advanced disease (eg, neoadjuvant therapy, adjuvant treatment after resection)

MODULE 5: Available Data with and Current Clinical Role of Anti-PD-1/PD-L1 Antibodies Alone or in Combination with Other Systemic Therapies for Patients with Metastatic NSCLC — Prof Peters

  • Implications of the Phase III KEYNOTE-042 and KEYNOTE-189 trial results; clinical and biologic factors affecting the selection of anti-PD-1/PD-L1 monotherapy versus combined chemotherapy/immune checkpoint inhibition
  • Key efficacy and safety findings from the Phase III IMpower150 study evaluating atezolizumab/bevacizumab in combination with carboplatin/paclitaxel for chemotherapy-naïve advanced nonsquamous NSCLC; implications of the recent FDA approval of this combination and proposed mechanisms of its effectiveness in specific subsets (eg, liver metastases, actionable tumor mutations)
  • Results from the Phase III IMpower130 and 132 trials of the addition of atezolizumab to chemotherapy for metastatic nonsquamous NSCLC
  • Role of anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced squamous NSCLC; results from the Phase III KEYNOTE-407 and IMpower131 trials

Target Audience:
This activity is intended for hematologists, medical oncologists and other healthcare providers involved in the treatment of lung cancer.

Learning Objectives and Goals:
At the conclusion of this activity, participants should be able to:

  • Appraise the recent FDA approval of anti-PD-L1 antibody consolidation therapy for patients with unresectable Stage III non-small cell lung cancer (NSCLC) who have not experienced disease progression after standard platinum-based chemotherapy concurrent with radiation therapy, and discern how this strategy can be appropriately and safely integrated into routine clinical practice.
  • Review recent FDA approvals and other therapeutic advances related to the use of anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy or chemobiologic therapy for newly diagnosed metastatic NSCLC.
  • Consider emerging research data and available guidelines informing the use of immune checkpoint inhibitors for patients with advanced small cell lung cancer (SCLC).
  • Recall the design of ongoing clinical trials evaluating anti-PD-1/PD-L1 antibodies in combination with other systemic therapies for NSCLC and SCLC, and counsel appropriate patients about availability and participation.
  • Review published research data documenting the safety and efficacy of EGFR tyrosine kinase inhibitors for metastatic NSCLC with an EGFR tumor mutation, and discern how this information should be applied outside of a research setting.
  • Communicate the efficacy and safety of approved and investigational ALK inhibitors to appropriate patients with NSCLC
  • Assess other oncogenic pathways mediating tumor growth in unique patient subgroups, and recall emerging data with commercially available and experimental agents exploiting these targets.

CME Credit Form:
A CME credit form will be given to each participant at the conclusion of the activity.

Accreditation Statement:
Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation Statement:
Research To Practice designates this live activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure Policy:
Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials.

Supporters:
This activity is supported by educational grants from AstraZeneca Pharmaceuticals LP, Genentech, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, and Merck.

Hilton Chicago
720 South Michigan Avenue
Chicago, IL 60605
Hotel Phone: (312) 922-4400

Meeting Room:
Grand Ballroom (Level 2)

Directions:
The Hilton Chicago hotel is located just 5 minutes (2.5 miles) north of the McCormick Place convention center, where the ASCO Annual Meeting is taking place.

 

Thank you for your interest in our educational program. At this time, online preregistration is closed. However, seats are still available for the conference. Onsite registration will be open starting at 6:30 PM on Friday, May 31st. If you are interested in attending, please visit our registration desk in the Grand Ballroom foyer located on the second level of the Hilton Chicago (720 Michigan Avenue, Chicago, IL).

Please note, onsite registrant seating will be prioritized for healthcare professionals directly involved in the treatment of patients, and meal service will be offered based on availability. If you have any questions, please feel free to contact us via email at Meetings@ResearchToPractice.com or call (800) 233-6153.